JPMorgan Chase & Co. Lowers Danaher (NYSE:DHR) Price Target to $300.00

Danaher (NYSE:DHR) had its price objective dropped by equities research analysts at JPMorgan Chase & Co. from $310.00 to $300.00 in a research note issued on Tuesday. The brokerage currently has an “overweight” rating on the conglomerate’s stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 34.46% from the company’s previous close.

DHR has been the topic of a number of other research reports. Raymond James lowered their price objective on Danaher from $300.00 to $275.00 and set an “outperform” rating on the stock in a report on Tuesday, January 21st. Guggenheim assumed coverage on shares of Danaher in a research report on Thursday, December 19th. They issued a “buy” rating and a $275.00 target price on the stock. Barclays reduced their target price on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. Citigroup dropped their target price on Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. Finally, TD Cowen lifted their target price on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $284.14.

Danaher Stock Performance

NYSE DHR opened at $223.12 on Tuesday. The stock’s fifty day moving average is $236.09 and its two-hundred day moving average is $253.66. The firm has a market capitalization of $161.15 billion, a P/E ratio of 42.58, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. Danaher has a fifty-two week low of $223.00 and a fifty-two week high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. During the same period in the previous year, the company earned $2.09 earnings per share. On average, research analysts anticipate that Danaher will post 7.5 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. FMR LLC increased its holdings in Danaher by 15.8% during the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after buying an additional 3,217,631 shares during the last quarter. Van ECK Associates Corp grew its position in Danaher by 6,862.7% during the fourth quarter. Van ECK Associates Corp now owns 929,868 shares of the conglomerate’s stock valued at $213,452,000 after acquiring an additional 916,513 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Danaher by 17.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after acquiring an additional 535,254 shares during the period. International Assets Investment Management LLC grew its holdings in Danaher by 40,196.5% in the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock worth $119,539,000 after acquiring an additional 428,897 shares during the last quarter. Finally, Montrusco Bolton Investments Inc. raised its holdings in shares of Danaher by 30.4% during the third quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock valued at $465,617,000 after acquiring an additional 397,671 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.